Can-Fite Biopharma (CANF) Starts Presentation at LD Micro Main Event
Can-Fite BioPharma Ltd. (NYSE: CANF) is an advanced clinical-stage drug development company with a platform technology designed to address multi-billion-dollar markets in the treatment of inflammatory diseases, cancer, and NAFLD/NASH. The company's lead drug candidate, Piclidenoson, is being evaluated in a global phase 3 trial as a first line therapy for rheumatoid arthritis and a phase 3 trial for moderate-to-severe psoriasis. Can-Fite's liver cancer drug, CF102, concluded patient enrollment in a phase 2 study for patients with liver cancer, and is slated to enter phase 2 for the treatment of non-alcoholic steatohepatitis. CF102 has shown proof of concept to potentially…







